Literature DB >> 2176819

Localization of In-111 antimyosin Fab and 99mTc-pyrophosphate in reperfusion myocardial infarction model.

D S Lee1, M C Lee, J K Chung, C S Koh, D H Moon.   

Abstract

The myocardial uptake of In-111 antimyosin Fab and Tc-99m pyrophosphate was studied in dogs undergoing coronary artery occlusion for 90 minutes followed by reperfusion. The regional myocardial blood flow was determined by injecting Sc-46 labeled microsphere and was related to the relative concentrations of In-111 antimyosin and Tc-99m pyrophosphate. There was an inverse linear correlation between In-111 antimyosin Fab localization and the regional blood flow in both the subendocardial (r = 0.81) and subepicardial myocardium (r = -0.80). The greatest uptake of antimyosin was observed in areas of severe blood flow reduction (0-10% of normal). On the other hand, there was no correlation between the Tc-99m pyrophosphate uptake and the degree of blood flow reduction. Maximal subendocardial localization of Tc-99m degree of blood flow reduction. Maximal subendocardial localization of Tc-99m pyrophosphate was observed in areas where the blood flow was reduced to 31-50% of the normal. In the case of the subepicardium, the greatest uptake was localized to areas of 0 to 10% of the normal flow. In addition, there was significant myocardial uptake in regions where the blood flow was minimally reduced (greater than 81%). This study suggests that In-111 antimyosin Fab is a specific and quantitative tool in the evaluation of myocardial necrosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2176819      PMCID: PMC4534996          DOI: 10.3904/kjim.1990.5.1.15

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  33 in total

1.  Ischemic tissue injury.

Authors:  R B Jennings; C E Ganote; K A Reimer
Journal:  Am J Pathol       Date:  1975-10       Impact factor: 4.307

2.  Noninvasive detection of human cardiac transplant rejection with indium-111 antimyosin (Fab) imaging.

Authors:  W Frist; T Yasuda; G Segall; B A Khaw; H W Strauss; H Gold; E Stinson; P Oyer; J Baldwin; M Billingham
Journal:  Circulation       Date:  1987-11       Impact factor: 29.690

3.  Myocardial damage delineated by indium-111 antimyosin Fab and technetium-99m pyrophosphate.

Authors:  B A Khaw; H W Strauss; R Moore; J T Fallon; T Yasuda; H K Gold; E Haber
Journal:  J Nucl Med       Date:  1987-01       Impact factor: 10.057

4.  Technetium-99m pyrophosphate myocardial uptake in patients with stable angina pectoris.

Authors:  J W Mason; R W Myers; E L Alderman; E B Stinson; M L Goris; J P Kriss
Journal:  Am J Cardiol       Date:  1977-07       Impact factor: 2.778

5.  Localization of radiolabeled cardiac myosin-specific antibody in myocardial infarcts. Comparison with technetium-99m stannous pyrophosphate.

Authors:  G A Beller; B A Khaw; E Haber; T W Smith
Journal:  Circulation       Date:  1977-01       Impact factor: 29.690

6.  Imaging of cardiac allograft rejection in dogs using indium-111 monoclonal antimyosin Fab.

Authors:  L J Addonizio; R E Michler; C Marboe; P E Esser; L L Johnson; D W Seldin; W M Gersony; P O Alderson; E A Rose; P J Cannon
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

7.  Mechanisms contributing to myocardial accumulation of technetium-99m stannous pyrophosphate after coronary arterial occlusion.

Authors:  R E Coleman; M S Klein; S A Ahmed; E S Weiss; W M Buchholz; B E Sobel
Journal:  Am J Cardiol       Date:  1977-01       Impact factor: 2.778

8.  Myocardial infarct imaging of antibodies to canine cardiac myosin with indium-111-diethylenetriamine pentaacetic acid.

Authors:  B A Khaw; F T Fallon; H W Strauss; E Haber
Journal:  Science       Date:  1980-07-11       Impact factor: 47.728

9.  Early imaging of experimental myocardial infarction by intracoronary administraion of 131I-labelled anticardiac myosin (Fab')2 fragments.

Authors:  B A Khaw; H K Gold; R C Leinbach; J T Fallon; W Strauss; G M Pohost; E Haber
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

10.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

Authors:  R A Kloner; C E Ganote; R B Jennings
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.